GCCA: Cement and Concrete Industry Launches Net Zero Accelerators Across the World – Including Focus on the ‘Global South’
The Global Cement and Concrete Association (GCCA) has today launched a series of Net Zero Accelerator initiatives to help national cement and concrete industries decarbonise in line with the GCCA’s 2050 Net Zero Global Industry Roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005500/en/
Cement and Concrete Industry Launches Net Zero Accelerators Across the World – Including Focus on the ‘Global South’ (Graphic: Business Wire)
The first wave of Accelerators will launch in Egypt, which later this year will be the host country for COP27, as well as in India, Thailand and Colombia. These countries combined represent approximately 10% of global cement and concrete production. Concrete, a local and durable material, is fundamental to overcoming sustainable development challenges which many parts of the world are facing, such as population growth, increasing urbanisation and the need for more resilient infrastructure and communities in the face of a rapidly changing climate.
Globally, cement and concrete manufacture accounts for around 7% of CO2 emissions. The global plan to eliminate these emissions by 2050 requires all parts of the world to accelerate the reductions in CO2 emissions. The Accelerator program will identify the barriers to decarbonisation in target countries and recommend key actions. This includes encouraging government policies that can have an immediate impact, such as better recycling, the use of waste as an alternative to fossil fuels, and other circular economy practices. It will also include identifying lighthouse projects that can fully eliminate emissions over the next decades, such as carbon capture utilisation and storage technologies.
Thomas Guillot, GCCA Chief Executive, said: “Last year our industry made a breakthrough net zero global commitment. This is the next logical step as we move our focus from a global roadmap to driving decisive local action.
“Concrete will continue to be the world’s most used building material for decades to come, meaning global cooperation between governments and industry is crucial to ensuring net zero targets are met. Our Net Zero Accelerators will offer collaboration and support to a number of target countries to help them decarbonise and align with the global roadmap. I’m proud to launch the first phase of the Accelerator program to assist these nations in embracing greener technologies and work towards a more sustainable future together. I now call on more partners around the world to join us and be part of this movement.”
His Excellency, Dr Mahmoud Mohieldin, COP 27 UNFCCC High-Level Champion of Egypt, said: “Much of the infrastructure the world needs to overcome our major global challenges – such as alleviating poverty, the need for clean water and energy, and safe, affordable housing – is yet to be built.
“Cement and concrete will play a critical role in delivering a healthier, more resilient, zero carbon world as the industry moves to rapidly and fully decarbonise. As such, we are pleased to support the Net Zero Accelerator initiative, helping developing countries achieve their decarbonisation targets, as we work to support all industries and countries with their climate ambitions to help build a more sustainable future for all. The full and willing participation of a sector which accounts for 7-8% of global CO2 emissions is critical to contribute to the goal of the 2015 Paris Climate Change Agreement to limit global warming well below 2°C degrees and as close as possible to 1.5°C.”
The accelerator programme comprises three elements – i. net zero national roadmaps including emissions forecasts, reduction levers, policy needs and the industry commitment; ii. identification and funding exploration for large scale carbon cutting ‘Lighthouse’ Projects; and iii. policy dialogues with national governments to help accelerate the transition.
The GCCA is partnering with the cement and concrete industry on the ground and will work closely with policymakers, designers, and the construction sector to help overcome procurement and resourcing challenges, as well as demonstrate the business case for greener technologies to be used on a wider scale.
The Accelerators will help align Phase 1 countries’ cement and concrete industries with the GCCA’s 2050 Net Zero Roadmap, which marked the biggest global commitment by a heavy industry to decarbonise when it was launched last year. The Roadmap sets out a path to fully decarbonise by 2050, a target aligned with the Paris Agreement to limit global warming to 1.5°C. The roadmap actions between now and 2030, to reduce concrete related emissions by 25%, will prevent almost 5 billion tonnes of carbon from entering the atmosphere compared to a business-as-usual scenario.
Lighthouse Projects and a new tranche of phase two Accelerators will be announced later this year.
-ends-
Notes to editors:
About the GCCA:
Launched in January 2018, the Global Cement and Concrete Association (GCCA) is dedicated to developing and strengthening the sector’s contribution to sustainable construction. The GCCA aims to foster innovation throughout the construction value chain in collaboration with industry associations as well as architects, engineers, and innovators. In this way, the association demonstrates how concrete solutions can meet global construction challenges and sustainable development goals while showcasing responsible industrial leadership in the manufacture and use of cement and concrete. The GCCA is headquartered in London, England. It complements and supports the work done by associations at the national and regional levels.
The GCCA works with key a range of partners. It co-leads the Mission Possible Partnership’s Concrete Action for Climate initiate with the World Economic Forum. The GCCA is also an official accelerator for the Race to Zero.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005500/en/
Contact information
Media enquiries should be directed to:
Ed Coy
GCCA@BCW-global.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
